Exai Bio’s next-generation RNA-based platform delivers actionable insight into cancer biology from a simple blood draw. Exai is revolutionizing how we diagnose, treat, and manage cancer. Using our novel RNA biomarkers, we found signals in what appeared to others as noise.

We’re a next-generation liquid biopsy company. Our mission is to enable a world where cancer can be detected early, diagnosed accurately, managed precisely, and ultimately cured.

Exai Bio is a next-generation liquid biopsy company. Our mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way,...

2023年8月3日 · Exai Bio is a next-generation liquid biopsy company with a mission to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way,...

2023年9月12日 · Exai Bio today announced non-small cell lung cancer (NSCLC) data further validating that its novel RNA- and generative AI-based liquid biopsy platform

2023年12月6日 · PALO ALTO, Calif.-- ( BUSINESS WIRE )--Exai Bio today announced new data demonstrating that its novel RNA-based and AI-driven liquid biopsy platform can detect breast cancer at the earliest...

Palo Alto, CA — Researchers at Exai Bio and UCSF have released data demonstrating that Exai’s novel, RNA-based liquid biopsy platform accurately detected breast cancer at the earliest stages and for the smallest tumors.

2024年4月8日 · In a new study, Exai’s novel RNA- and AI-based liquid biopsy platform demonstrated stage I breast cancer detection sensitivity of 90% and ductal carcinoma in situ (DCIS) sensitivity of 88%,...

Next-generation liquid biopsy company, Exai Bio, presented data from its scientific research program on the discovery and validation of tumor-specific, orphan non-coding RNAs (oncRNAs), and the validation of artificial intelligence (AI) profiling of oncRNAs to accurately detect cancers of diverse tissue origins.

2023年12月12日 · Exai Bio’s RNA and AI-based liquid biopsy platform represents an advance in the early detection of breast cancer, offering a level of accuracy that surpasses traditional DNA-based approaches.